-
WuXi Department moved overseas
Time of Update: 2022-08-15
During the market downturn, WuXi's excessive capital operation has not changed . WuXi AppTec plans to issue no more than 78. 43 million H shares, which will raise more than HK$6 billion at a 20% disc
-
"Black Technology" Comes Out!
Time of Update: 2022-08-15
Compared with plasmid-dependent unassisted systems, the production of rAAV2 using TESSA™ technology can increase vector yield by approximately 40 times ; in terms of quality, AAV vectors increase the cumulative transfection capacity of cells with the gene of interest by more than 2400 times (based on TESSA).
-
Professor Chen Yao: Real-world research from the eyes of a statistician
Time of Update: 2022-08-15
Yao Chen, director of the Medical Statistics Office of Peking University First Hospital, "How to use high-quality real-world data research to break the circle" There are a thousand Hamlets in the eyes of a thousand people.
-
Large-scale nucleic acid cannot be covered by medical insurance, who will pay for the tens of billions of tests?
Time of Update: 2022-08-15
". " 8:00 Jianwen asked people from the medical insurance departments of many provinces and cities, and their areas are basically the same as the current medical insurance policies - only the nucleic acid costs of fever outpatients, inpatients, and new crown patients are covered, while the nucleic acid testing costs for large-scale populations is paid for by the finances .
-
But the PK drug king, Xiumeile, a new drug for psoriasis, has been approved for marketing, and the domestic same case sold for only 30 million yuan. It was once praised as the "diamond standard" in this field...
Time of Update: 2022-08-15
The Chinese pharmaceutical field has long been eager for FIC, but when we discover FIC, how will we face it? If the FDA hadn't approved the drug, this FIC drug with deep roots in China might have bee
-
Behind the World's Largest M&A in the New Year: The $10 Billion Migraine Market and the Popular Target CGRP
Time of Update: 2022-08-15
. Upon completion of the transaction, Pfizer will acquire Biohaven's calcitonin gene-related peptide (CGRP) program, including: rimegepant (US trade name: Nurtec ODT; EU trade name: Vydura); Zavegepant intended for acute intranasal spray treatment of migraine , and is being developed as an oral softgel for chronic migraine prevention; and 5 preclinical programs targeting CGRP .
-
Traditional VS Freshmen: Who Qualifies as an Innovative Pharmaceutical Company?
Time of Update: 2022-08-15
The Q1 sales and year-on-year growth rates of a total of 11 pharmaceutical companies in 2022 are shown in Table 1: From the perspective of data, analyze the competitive landscape and product power of mainstream pharmaceutical companies .
-
Where is GMP going in the "post-epidemic era"?
Time of Update: 2022-08-15
I think that since the representatives of the ears can hear all kinds of ideas, then this stage, let's call it the third stage, GMP still There are many ways to play: So far, the GMP fortress has been completed, a system with direction, engines and boundaries, and self-optimization capabilities (continuous improvement in quality management, life cycle concept, etc.
-
10-year picture of China's innovative drug development
Time of Update: 2022-08-15
Annual number of NDA applications for innovative drugs (Source: Nature Reviews Drug Discovery) Especially in 2021, the number of innovative drugs applied for listing in China reached a new high, reaching 83, including 51 domestic new drugs and 32 imported new drugs; in terms of drug types, 38 chemical drugs, 33 biological drugs (covering Antibody, recombinant protein, ADC, vaccine, cell therapy, allergen products) and 12 varieties of traditional Chinese medicine .
-
Pfizer announces it will sell all of its patented medicines at low prices to 45 poor countries around the world
Time of Update: 2022-08-12
Breast cancer drug Ibrance Pfizer said it will sell all of its patented medicines, including Paxlovid, an oral drug used to treat COVID-19, and a popular patient-friendly drug, to the aforementioned countries at nonprofit prices.
-
One article to understand the competitive landscape of the domestic biosimilar drug market
Time of Update: 2022-08-12
Geleli (Adalimumab biosimilar ) Pubixic (bevacizumab biosimilar) Judging from the sales performance of the currently listed biosimilar drugs, they have achieved doubled performance growth, and the gross profit margin is quite high.
-
Revolutionary Pioneer Bi Jingquan connects drug review, medical reform and the future
Time of Update: 2022-08-12
. The opinions pointed out that the main tasks of the reform include adjusting the scope of new drugs, promoting the consistency evaluation of generic drugs, implementing special review and approval for innovative drugs, developing a drug marketing license holder system, and improving clinical trial approval .
-
Express develops breakthrough covalent drugs, Xinrui completes $75 million in Series A financing
Time of Update: 2022-08-12
Cysteine is uncommon in proteins, thus limiting the number of targets that can be targeted by this mechanism Terremoto's technology platform aims to expand the types of amino acids that covalent drugs can bind to and develop covalent drugs that target lysine binding .
-
The ranking of the "Four Little Dragons" has changed dramatically, and the R&D format is reshaping the industry.
Time of Update: 2022-08-12
Image source | Snowball Judging from the recent news released by various companies and the trend of stock price changes, there are two main drivers behind this incident, one is the increasingly serious involution of the PD-1 market, and the other is that investors' focus has shifted to the research and development of new crown drugs .
-
Differentiated layout, domestic CAR-Ts compete to appear at the 2022 ASCO annual meeting
Time of Update: 2022-08-10
foreword On May 26, 2022, the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting Abstract was released online, in which a number of domestic CAR-T cell therapy products were unveiled, with product indications covering hematological tumors and solid tumors, and target selection Diversified, with different technical routes, the overall presentation is a 3D three-dimensional differentiated layout , showing the strong strength of the domestic CAR-T R&D pipeline.
-
Only 7 months: Pfizer's new drug has been approved for marketing in the UK, Japan, Europe, and the United States
Time of Update: 2022-08-10
】 However, Pfizer has been equally good at getting new drugs to market at the same time as major regulatory agencies around the world:However, Pfizer has been equally good at getting new drugs to market at the same time as major regulatory agencies around the world: On April 11 this year, the National Medical Products Administration (NMPA) approved Pfizer’s Class 1 innovative drug abrucitinib (trade name: Cibinqo) through the priority review and approval process.
-
In the non-oncology field, the first domestic IND for CAR-T treatment of autoimmune diseases was accepted
Time of Update: 2022-08-10
They are CD19/CD22 positive relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL) and relapsed/refractory acute B-lymphocytic leukemia (B-ALL), respectively, and have been granted an "orphan drug" by the FDA Designation (ODD) In addition to CT103A, Reindeer Bio has more than 10 varieties under development at different stages of development, and its self-developed innovative product CT120 (full human CD19/CD22 dual-target CAR-T cell injection) has entered the clinical research stage.
-
Hub-and-spoke: a new model for innovative drug development/investment
Time of Update: 2022-08-10
Actively seize opportunities such as license-out cooperation or sale of new drug assets of subsidiaries; making assets that big pharmaceutical companies are interested in is an option .
-
Analysis of the stock price and market value of 14 Chinese pharmaceutical companies affected by the pre-delisting in the United States
Time of Update: 2022-08-10
: Gracell Bio, Tianyan Pharmaceutical, 1 Drug Network , Burning Rock Medicine, Tianjing Bio, Genetron Health, Kexing Bio, 1 Drug Network Tianjing Bio, Pharma Times will continue to summarize and report key information in this regard, and share it with the majority of fellow pharmacists.
-
Professor Ye Yuru, Honorary President of the Association, was appointed as the President of the Hong Kong University of Science and Technology
Time of Update: 2022-08-10
---- HKBMIA Hong Kong Biomedical Innovation Association---- HKBMIA is committed to building an innovative and international biomedical technology industry platform for Hong Kong .
---- HKBMIA Hong Kong Biomedical Innovation Association---- HKBMIA is committed to building an innovative and international biomedical technology industry platform for Hong Kong .
